논문 상세보기

대한내과학회> The Korean Journal of Internal Medicine> Current state and prospects of gout treatment in Korea

KCI등재SCOUPUS

Current state and prospects of gout treatment in Korea

Eun Hye Park , Sang Tae Choi , Jung Soo Song
  • : 대한내과학회
  • : The Korean Journal of Internal Medicine 37권4호
  • : 연속간행물
  • : 2022년 07월
  • : 719-731(13pages)
The Korean Journal of Internal Medicine

DOI


목차

INTRODUCTION
GENERAL PRINCIPLES OF TREATMENT FOR GOUT
NONPHARMACOLOGIC TREATMENT FOR GOUT
PHARMACOLOGIC TREATMENT FOR GOUT
MANAGEMENT OF COMORBITIES AND CONCOMITANT MEDICATIONS
CONCLUSIONS
REFERENCES

키워드 보기


초록 보기

Effective management of gout includes the following: appropriate control of gout flares; lifestyle modifications; management of comorbidities; and long-term urate-lowering therapy (ULT) to prevent subsequent gout flares, structural joint damage, and shortening of life expectancy. In addition to traditional treatments for gout, novel therapies have been introduced in recent years. Indeed, new recommendations for the management of gout have been proposed by various international societies. Although effective and safe medications to treat gout have been available, management of the disease has continued to be suboptimal, with poor patient adherence to ULT and failure to reach serum urate target. This review outlines recent progress in gout management, mainly based on the latest published guidelines, and specifically provides an update on efficient strategies for implementing treatment, efficacy and safety of specific medications for gout, and cardiovascular outcomes of ULT. In particular, we reviewed gout management approaches that can be applied to a Korean population.

UCI(KEPA)

간행물정보

  • : 의약학분야  > 내과학
  • : KCI등재
  • : SCOPUS
  • : 격월
  • : 1226-3303
  • : 2005-6648
  • : 학술지
  • : 연속간행물
  • : 1986-2022
  • : 2751


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

37권5호(2022년 09월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCOPUS

1Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α

저자 : Jihye Park , Jae Hee Cheon

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 895-905 (11 pages)

다운로드

(기관인증 필요)

초록보기

The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties. The relapses and complications of active IBD mandate various medications. Nevertheless, hospitalization, emergency room visits, or surgery may be required, resulting in a socioeconomic burden. Great advances have been made in the development of new therapeutic options for IBD to achieve induction and maintenance remission. Nevertheless, conventional therapy is still the mainstay in the treatment of IBD. This review article provides an update on recent advances in conventional therapies, including 5-aminosalicylates, corticosteroids, immunomodulators, and anti-tumor necrosis factor-α agents to treat IBD.

KCI등재 SCOPUS

2Inflammatory bowel disease in Korea: epidemiology and pathophysiology

저자 : Jung Won Lee , Chang Soo Eun

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 895-904 (10 pages)

다운로드

(기관인증 필요)

초록보기

Inflammatory bowel disease (IBD) refers to a group of disorders, including Crohn's disease and ulcerative colitis, that exhibit similar but distinct manifestations. These diseases are characterized by refractory and chronic inflammation of the bowel. IBD is usually accompanied by severe symptoms. When a patient presents with suspected IBD, physicians encounter various challenges in terms of diagnosis and treatment. In addition, given such characteristics, the associated medical expenses gradually increase. Although IBD was formerly known as a disease of Western countries, the incidence and prevalence are increasing in Korea. Korean investigators have accumulated a great deal of knowledge about the regional characteristics and epidemiology of the disease, especially via well-organized, joint cohort studies. Against this background, this article describes the epidemiology of IBD in Korea compared to that in the West. In addition, an overview of the pathophysiology of the disease is provided, focusing on the latest results.

KCI등재 SCOPUS

3Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs

저자 : Soo-young Na , You Sun Kim

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 906-919 (14 pages)

다운로드

(기관인증 필요)

초록보기

The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the rates of complications and surgery. Although anti-TNF agents have changed the course of IBD, there are unmet needs in terms of primary and secondary non-responses and side effects such as infections and malignancies. Novel biologics and small-molecule drugs have been developed for IBD, and the medical treatment options have improved. These drugs include sphingosine-1-phosphate receptor modulators and anti-integrins to block immune cell migration, and cytokine and Janus kinase inhibitors to block immune cell communications. In this review, we discuss the approved novel biologics and small-molecule drugs, including several of those in the late stages of development, for the treatment of IBD.

KCI등재 SCOPUS

4Vaccination strategies for Korean patients with inflammatory bowel disease

저자 : Yoo Jin Lee , Eun Soo Kim

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 920-930 (11 pages)

다운로드

(기관인증 필요)

초록보기

Patients with inflammatory bowel disease (IBD) are vulnerable to vaccine-preventable infectious diseases. Immunosuppressive drugs, which are often used to manage IBD, may increase this vulnerability and attenuate vaccine efficacy. Thus, healthcare providers should understand infectious diseases and schedule vaccinations for them to reduce the infection-related burden of patients with IBD. All patients with IBD should be assessed in terms of immunity to vaccine-preventable diseases at the time of IBD diagnosis, and be vaccinated appropriately. Vaccination is becoming more important because of the unprecedented coronavirus disease 2019 (COVID-19) global health crisis. This review focuses on recent updates to vaccination strategies for Korean patients with IBD.

KCI등재 SCOPUS

52022 Consensus statement on the management of familial hypercholesterolemia in Korea

저자 : Chan Joo Lee , Minjae Yoon , Hyun-jae Kang , Byung Jin Kim , Sung Hee Choi , In-kyung Jeong , Sang-hak Lee

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 931-944 (14 pages)

다운로드

(기관인증 필요)

초록보기

Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and < 70 or < 55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C > 500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.

KCI등재 SCOPUS

6The role of neutrophils in the pathogenesis of IPF

저자 : Yangjin Jegal

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 945-946 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCOPUS

7Denosumab, an effective osteoporosis treatment option for men

저자 : Sung Hye Kong

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 947-948 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCOPUS

8Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis

저자 : Soo-kyung Park , Sang-bum Kang , Sangsoo Kim , Tae Oh Kim , Jae Myung Cha , Jong Pil Im , Chang Hwan Choi , Eun Soo Kim , Geom Seog Seo , Chang Soo Eun , Dong Soo Han , Dong Il Park

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 949-962 (14 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: In ulcerative colitis (UC) patients, Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, evidence of the ability of EcN to increase health-related quality of life or induce remission remains scarce. We investigated the efficacy of EcN as an add-on therapy for UC.
Methods: In this multicentre, double-blind, randomised, placebo-controlled study, a total of 133 UC patients were randomly assigned to receive either EcN or placebo once daily for 8 weeks. Inflammatory bowel disease questionnaire (IBDQ) scores (primary endpoint) and clinical remission and response rates (secondary endpoints) were compared (Clinical trial registration number: NCT04969679).
Results: In total, 118 patients (EcN, 58; placebo, 60) completed the study. The number of patients reaching the primary endpoint did not differ between the EcN and placebo groups (30 [51.7%] vs. 31 [51.7%]; per-protocol analysis, p = 1.0; intention-to-treat analysis, p = 0.86). However, significantly fewer patients in the EcN group exhibited a decreased IBDQ score (1 [1.7%] vs. 8 [13.3%]; per-protocol analysis, p = 0.03; intention-to-treat analysis, p = 0.02). Moreover, a significantly higher number of patients in the EcN group displayed clinical response at 4 weeks (23 [39.7%] vs. 13 [21.7%], p = 0.04) and endoscopic remission at 8 weeks (26 [46.4%] vs. 16 [27.1%], p = 0.03).
Conclusions: Although the number of patients reaching the primary endpoint did not differ between the EcN and placebo groups, EcN was found to be safe and effective in preventing the exacerbation of IBDQ scores and achieving clinical responses and endoscopic remission in patients with mild-to-moderate UC.

KCI등재 SCOPUS

9Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease

저자 : Ji Eun Ryu , Myeong Jun Song , Seok-hwan Kim , Jung Hyun Kwon , Sun Hong Yoo , Soon Woo Nam , Hee Chul Nam , Hee Yeon Kim , Chang Wook Kim , Hyun Yang , Si Hyun Bae , Do Seon Song , U Im Chang , Jin Mo

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 958-968 (11 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea.
Methods: In a retrospective, multicenter cohort study, 362 patients were enrolled from 2015 to 2019. The effectiveness and safety of DAAs including glecaprevir/pibrentasvir, sofosubvir/ribavirin, ledipasvir/sofosbuvir, and daclatasvir/asunaprevir were analyzed for patients according to CKD stage. We evaluated sustained virologic response at week 12 after treatment (SVR12) as primary endpoint. The effectiveness and safety were also evaluated according to CKD stage.
Results: Among 362 patients, 307 patients completed DAAs treatment and follow-up period after end of treatment. The subjects comprised 87 patients (62 with CKD stage 3 and 25 with CKD stage (4-5), of whom 22 were undergoing hemodialysis). HCV patients with CKD stage 1 and 2 (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 ㎡) showed SVR12 of 97.2% and 95.4% respectively. SVR12 of CKD stage 3 and 4-5 (eGFR < 60 mL/min/1.73 ㎡) patients was 91.9% and 91.6% respectively. Patients undergoing hemodialysis achieved SVR12 (90.9%). Treatment failure of DAAs in stage 1, 2, 3, and 4-5 was 2.8%, 2.7%, 1.6%, and 4%. DAAs showed good safety profile and did not affect deterioration of renal function.
Conclusions: DAAs shows comparable SVR12 and safety in CKD patients (stage 3, 4, and 5) with HCV compared with patients with stage 1 and 2. The effectiveness and safety of DAAs may be related to the treatment duration. Therefore, it is important to select adequate regimens of DAAs and to increase treatment adherence.

KCI등재 SCOPUS

10Factors associated with the risk of colorectal neoplasia in young adults under age 40

저자 : Ilsoo Kim , Han Hee Lee , Young Jae Ko , Ho Eun Chang , Dae Young Cheung , Bo-in Lee , Young-seok Cho , Jin Il Kim , Myung-gyu Choi

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 5호 발행 연도 : 2022 페이지 : pp. 969-978 (10 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Recent epidemiologic studies have shown a continued increase in colorectal cancer incidence among younger adults. Little is known about the factors that contribute to the development of young-onset colorectal neoplasia (CRN).
Methods: A cross-sectional analysis was performed for individuals younger than 40 years who underwent colonoscopy in Seoul St. Mary's Hospital and its affiliated health screening center. High-risk CRN was defined as adenoma or sessile serrated lesion ≥ 10 mm, with three or more adenomas, villous histology, high grade dysplasia, or carcinoma.
Results: Of these 13,621 included participants, 2,023 (14.9%) had one and more CRN. Young patients with CRN tended to be elderly, male, obese, smoker, having a habit of drinking, and having comorbidities such as hypertension, dyslipidemia, diabetes, and chronic kidney disease. In a multivariate analysis adjusted for age, sex, obesity, smoking status, and alcohol intake, old age (odds ratio [OR], 1.086; 95% confidence interval [CI], 1.054 to 1.119), male sex (OR, 1.748; 95% CI, 1.247 to 2.451), obesity (OR, 1.439; 95% CI, 1.133 to 1.828), and smoking (OR, 1.654; 95% CI, 1.287 to 2.127) were independent risk factors for overall CRN. Obesity and smoking as two modifiable factors increased the risk for high-risk CRN even more than for overall CRN (OR, 1.734; 95% CI, 1.168 to 2.575 and OR, 1.797; 95% CI, 1.172 to 2.753, respectively).
Conclusions: Obesity and smoking were modifiable risk factors for CRN in young adults. They increased the risk for high-risk CRN even more than for overall CRN. A colonoscopy might be beneficial for young individuals with these factors.

123
권호별 보기
같은 권호 다른 논문
| | | | 다운로드

KCI등재SCOUPUS

1Executive summary of the Korean Society of Nephrology 2021 clinical practice guideline for optimal hemodialysis treatment

저자 : Ji Yong Jung , Kyung Don Yoo , Eunjeong Kang , Hee Gyung Kang , Su Hyun Kim , Hyoungnae Kim , Hyo Jin Kim , Tae-jin Park , Sang Heon Suh , Jong Cheol Jeong , Ji-young Choi , Young-hwan Hwang , Miyoung Choi

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 701-718 (18 pages)

다운로드

(기관인증 필요)

초록보기

The Korean Society of Nephrology (KSN) has published a clinical practice guideline (CPG) document for maintenance hemodialysis (HD). The document, 2021 Clinical Practice Guideline on Optimal HD Treatment, is based on an extensive evidence-oriented review of the benefits of preparation, initiation, and maintenance therapy for HD, with the participation of representative experts from the KSN under the methodologists' support for guideline development. It was intended to help clinicians participating in HD treatment make safer and more effective clinical decisions by providing user-friendly guidelines. We hope that this CPG will be meaningful as a recommendation in practice, but not on a regulatory rule basis, as different approaches and treatments may be used by health care providers depending on the individual patient's condition. This CPG consists of eight sections and 15 key questions. Each begins with statements that are graded by the strength of recommendations and quality of the evidence. Each statement is followed by a summary of the evidence supporting the recommendations. There are also a link to full-text documents and lists of the most important reports so that the readers can read further (most of this is available online).

KCI등재SCOUPUS

2Current state and prospects of gout treatment in Korea

저자 : Eun Hye Park , Sang Tae Choi , Jung Soo Song

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 719-731 (13 pages)

다운로드

(기관인증 필요)

초록보기

Effective management of gout includes the following: appropriate control of gout flares; lifestyle modifications; management of comorbidities; and long-term urate-lowering therapy (ULT) to prevent subsequent gout flares, structural joint damage, and shortening of life expectancy. In addition to traditional treatments for gout, novel therapies have been introduced in recent years. Indeed, new recommendations for the management of gout have been proposed by various international societies. Although effective and safe medications to treat gout have been available, management of the disease has continued to be suboptimal, with poor patient adherence to ULT and failure to reach serum urate target. This review outlines recent progress in gout management, mainly based on the latest published guidelines, and specifically provides an update on efficient strategies for implementing treatment, efficacy and safety of specific medications for gout, and cardiovascular outcomes of ULT. In particular, we reviewed gout management approaches that can be applied to a Korean population.

KCI등재SCOUPUS

3Perioperative and anesthetic management of patients with rheumatoid arthritis

저자 : Hae-rim Kim , Seong-hyop Kim

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 732-739 (8 pages)

다운로드

(기관인증 필요)

초록보기

Our understanding and management of rheumatoid arthritis (RA) have greatly improved, but perioperative and anesthetic management remain challenging. RA is not limited to joints; systemic evaluation is thus required when planning perioperative management. Especially, careful airway evaluation is needed; management of airway-related arthritis is challenging. A multidisciplinary approach is essential to prevent complications without exacerbating RA disease activity. Guidelines published in 2017 are available for perioperative management of anti-rheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. However, the guidelines focus only on anti-rheumatic medications, and do not consider all aspects of perioperative management (including anesthesia). Here, we discuss the perioperative and anesthetic management of patients with RA.

KCI등재SCOUPUS

4Predictors of recurrent acute myocardial infarction despite initially successful percutaneous coronary intervention: back to the basic

저자 : Seonghoon Choi

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 740-741 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재SCOUPUS

6Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models

저자 : Seong Hee Kang , Hyung Joon Yim , Ji-won Hwang , Mi-jung Kim , Young-sun Lee , Young Kul Jung , Hyungshin Yim , Baek-hui Kim , Hae-chul Park , Yeon Seok Seo , Ji Hoon Kim , Jong Eun Yeon , Soon Ho Um ,

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 745-762 (18 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Efficient anti-fibrotic therapies are required for the treatment of liver cirrhosis. Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and cyclooxygenase-2 (COX-2) inhibitors have been reported to have anti-fibrotic effects. Here, we investigated whether combined treatment with a statin and a COX-2 inhibitor has synergistic anti-fibrotic effects.
Methods: The effects of treatment strategies incorporating both simvastatin and a COX-2 inhibitor, NS-398, were investigated using an immortalized human hepatic stellate cell line (LX-2) and a hepatic fibrosis mouse model developed using thioacetamide (TAA) in drinking water. Cellular proliferation was investigated via 5-bromo-2-deoxyuridine uptake. Pro- and anti-apoptotic factors were investigated through Western blotting and real-time polymerase chain reaction analysis.
Results: The evaluation of the anti-proliferative effects on LX-2 cells showed that the observed effects were more pronounced with combination therapy than with single-drug therapy. Moreover, hepatic fibrosis and collagen deposition decreased significantly in TAA-treated mice in response to the combined treatment strategy. The mechanisms underlying the anti-fibrotic effects of the combination therapy were investigated. The effects of the combination therapy were correlated with increased expression levels of extracellular signal-regulated kinase 1/2 signaling molecules, upregulation of the Bax/Bcl- 2 signaling pathway, inhibition of the transforming growth factor-β signaling pathway, and inhibition of tissue inhibitor of matrix metalloproteinases 1 and 2.
Conclusions: The combination of simvastatin and NS-398 resulted in a synergistic anti-fibrotic effect through multiple pathways. These findings offer a theoretical insight into the possible clinical application of this strategy for the treatment of advanced liver diseases with hepatic fibrosis.

KCI등재SCOUPUS

7Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study

저자 : Eileen L. Yoon , Sang Bong Ahn , Dae Won Jun , Yong Kyun Cho , Do Seon Song , Jae Yoon Jeong , Hee Yeon Kim , Young Kul Jung , Myeong Jun Song , Sung Eun Kim , Hyoung Su Kim , Soung Won Jeong , Sang Gyune K

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 757-770 (14 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: L-carnitine is potentially beneficial in patients with hepatic encephalopathy (HE). We aimed to evaluate the impact of L-carnitine on the quality of life and liver function in patients with liver cirrhosis and covert HE.
Methods: We conducted an investigator-initiated, prospective, multi-center, double-blind, randomized phase III trial in patients with covert HE. A total of 150 patients were randomized 1:1 to L-carnitine (2 g/day) or placebo for 24 weeks. Changes in quality of life and liver function were assessed at 6 months. The model for end-stage liver disease (MELD), the 36-Item Short Form Survey (SF-36), the psychometric hepatic encephalopathy score (PHES), and the Stroop Test were evaluated in all patients.
Results: The total SF-36 score significantly improved in the L-carnitine group after 24 weeks (difference: median, 2; interquartile range, 0 to 11; p < 0.001); however, these values were comparable between the two groups. Furthermore, there was a significant ordinal improvement in PHES scores among patients with minimal HE who were in the L-carnitine group (p = 0.007). Changes in the total carnitine level also positively correlated with improvements in the Stroop test in the L-carnitine group (color test, r = 0.3; word test, r = 0.4; inhibition test, r = 0.5; inhibition/switching test, r = 0.3; all p < 0.05). Nevertheless, the MELD scores at week 24 did not differ between the groups.
Conclusions: Twenty-four weeks of L-carnitine supplementation was safe but ineffective in improving quality of life and liver function.

KCI등재SCOUPUS

8Clinical outcomes of metachronous recurrence of gastric epithelial neoplasia based on Helicobacter pylori infection status and microsatellite stability

저자 : Yeon-ji Kim , Jaeyoung Kim , Woo Chul Chung

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 768-776 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Helicobacter pylori eradication may prevent the recurrence of gastric epithelial neoplasia after endoscopic treatment. However, H. pylori eradication therapy is unlikely to prevent gastric cancer. This study determined the long-term results and clinical outcomes of patients with gastric epithelial neoplasia based on H. pylori infection status and microsatellite stability (MSS).
Methods: Patients diagnosed with gastric epithelial neoplasia who underwent an endoscopic mucosal resection or submucosal dissection between 2004 and 2010 were included in this retrospective study. During the follow-up period (range, 4 to 14 years), disease recurrence was monitored, and tissue examinations were conducted for seven sets of microsatellite loci initially linked to the tumour suppressor gene locus. When H. pylori infection was identified, patients underwent eradication therapy.
Results: The patients (n = 120) were divided into three groups: H. pylori-negative with MSS, H. pylori-positive with MSS, and microsatellite instability (MSI). After H. pylori eradication, the rate of metachronous recurrence was significantly different in the MSI (28.2%) and MSS groups (3.7%, p < 0.01). The mean duration of recurrence was 77 months (range, 24 to 139) in the MSI group. There was no recurrence after eradication therapy in patients who were positive for H. pylori in the MSS group.
Conclusion: H. pylori eradication could help prevent gastric cancer recurrence in patients with stable microsatellite loci. Careful, long-term monitoring is required in patients with unstable microsatellite loci.

KCI등재SCOUPUS

9Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention

저자 : Sang Hun Lee , Myung Ho Jeong , Joon Ho Ahn , Dae Young Hyun , Kyung Hoon Cho , Min Chul Kim , Doo Sun Sim , Young Joon Hong , Ju Han Kim , Youngkeun Ahn , Jin Yong Hwang , Weon Kim , Jong Seon Park , C

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 777-790 (14 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Recurrent acute myocardial infarction (AMI) is an adverse cardiac event in patients with a first AMI. The predictors of recurrent AMI after the first AMI in patients who underwent successful percutaneous coronary intervention (PCI) have not been elucidated.
Methods: We analyzed the data collected from 9,869 patients (63.2 ± 12.4 years, men:women = 7,446:2,423) who were enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health between November 2011 and October 2015, had suffered their first AMI and had received successful PCI during the index hospitalization. Multivariable logistic regression analysis was performed to identify the independent predictors of recurrent AMI following the first AMI.
Results: The cumulative incidence of recurrent AMI after successful PCI was 3.6% (359/9,869). According to the multivariable logistic regression analysis, the significant predictive factors for recurrent AMI were diabetes mellitus, renal dysfunction, atypical chest pain, and multivessel disease.
Conclusions: In this Korean prospective cohort study, the independent predictors of recurrent AMI after successful PCI for the first AMI were diabetes mellitus, renal dysfunction, atypical chest pain, and multivessel disease.

KCI등재SCOUPUS

10Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea

저자 : Seok Oh , Myung Ho Jeong , Kyung Hoon Cho , Min Chul Kim , Doo Sun Sim , Young Joon Hong , Ju Han Kim , Youngkeun Ahn

발행기관 : 대한내과학회 간행물 : The Korean Journal of Internal Medicine 37권 4호 발행 연도 : 2022 페이지 : pp. 786-799 (14 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Little is known about the clinical characteristics and treatment outcomes of ST-segment elevation myocardial infarction (STEMI) in Korea during the coronavirus disease 2019 (COVID-19) era. We aimed to evaluate the clinical characteristics and treatment outcomes of patients with STEMI in the COVID-19 era.
Methods: A total of 588 consecutive patients with STEMI who underwent primary percutaneous coronary intervention were included in this study. The patients were categorized into the COVID-19 (from January 20, 2020 to December 31, 2020) and control groups (from January 20, 2019 to December 31, 2019).
Results: The COVID-19 group showed pre-hospital and in-hospital delays than the control group. The control group underwent more thrombus aspiration and had a higher proportion of left main coronary artery diseases, while the COVID-19 group had a higher proportion of multivessel diseases with a marked increase in the number and total length of stents than the control group. As for the prescribed medications, the COVID-19 group was administered more beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins than the control group. The clinical outcomes were comparable between the groups, except for higher incidences of atrioventricular block and temporary pacemaker implantation in the COVID-19 group.
Conclusions: Reperfusion after STEMI treatment during the COVID-19 period was delayed; therefore, efforts should be made to improve on reperfusion.

123
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기